Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention

Peter Tajti, Iosif Xenogiannis, Allison Hall, M. Nicholas Burke, Ivan Chavez, Santiago Garcia, Mario Gössl, Michael Mooney, Anil Poulose, Paul Sorajja, Yale Wang, Evangelia Vemmou, Ilias Nikolakopoulos, Pamela Morley, Bavana Venkata Rangan, Imre Ungi, Emmanouil S Brilakis

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires administration of large contrast volume. The DyeVert system (Osprey Medical) is a disposable, Food and Drug Administration (FDA)-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in cardiac catheterization. METHODS: We compared the procedural outcomes of patients in whom the DyeVert system was used vs those in whom it was not used during CTO-PCI at a single center between 2017 and 2018. RESULTS: The DyeVert system was used in 39 of 134 CTO-PCIs performed in 130 patients (30%). Most patients (79%) were men and the mean age was 66.6 ± 10.9 years. The most common target vessel was the right coronary artery (54.5%), followed by the left anterior descending artery (26.1%), and circumflex artery (15.7%). The median contrast volume used in DyeVert patients was significantly lower (200 mL [interquartile range, 153-256 mL] vs 250 mL [interquartile range, 170-303 mL]; P=.04). There were no in-hospital major complications with the DyeVert system, nor device-related procedural complications. One patient in the DyeVert group had contrast-induced nephropathy following CTO-PCI that did not require dialysis. CONCLUSION: Use of the DyeVert system is feasible during CTO-PCI and may reduce the contrast volume administered to the patient. Additional larger studies with a primary clinical endpoint are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalThe Journal of invasive cardiology
Volume31
Issue number9
StatePublished - Sep 1 2019

Fingerprint

Percutaneous Coronary Intervention
Arteries
Equipment and Supplies
United States Food and Drug Administration
Cardiac Catheterization
Dialysis
Coronary Vessels

Keywords

  • acute outcomes
  • chronic total occlusion
  • contrast reduction
  • percutaneous coronary intervention

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Tajti, P., Xenogiannis, I., Hall, A., Burke, M. N., Chavez, I., Garcia, S., ... Brilakis, E. S. (2019). Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention. The Journal of invasive cardiology, 31(9), 253-259.

Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention. / Tajti, Peter; Xenogiannis, Iosif; Hall, Allison; Burke, M. Nicholas; Chavez, Ivan; Garcia, Santiago; Gössl, Mario; Mooney, Michael; Poulose, Anil; Sorajja, Paul; Wang, Yale; Vemmou, Evangelia; Nikolakopoulos, Ilias; Morley, Pamela; Rangan, Bavana Venkata; Ungi, Imre; Brilakis, Emmanouil S.

In: The Journal of invasive cardiology, Vol. 31, No. 9, 01.09.2019, p. 253-259.

Research output: Contribution to journalArticle

Tajti, P, Xenogiannis, I, Hall, A, Burke, MN, Chavez, I, Garcia, S, Gössl, M, Mooney, M, Poulose, A, Sorajja, P, Wang, Y, Vemmou, E, Nikolakopoulos, I, Morley, P, Rangan, BV, Ungi, I & Brilakis, ES 2019, 'Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention', The Journal of invasive cardiology, vol. 31, no. 9, pp. 253-259.
Tajti P, Xenogiannis I, Hall A, Burke MN, Chavez I, Garcia S et al. Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention. The Journal of invasive cardiology. 2019 Sep 1;31(9):253-259.
Tajti, Peter ; Xenogiannis, Iosif ; Hall, Allison ; Burke, M. Nicholas ; Chavez, Ivan ; Garcia, Santiago ; Gössl, Mario ; Mooney, Michael ; Poulose, Anil ; Sorajja, Paul ; Wang, Yale ; Vemmou, Evangelia ; Nikolakopoulos, Ilias ; Morley, Pamela ; Rangan, Bavana Venkata ; Ungi, Imre ; Brilakis, Emmanouil S. / Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention. In: The Journal of invasive cardiology. 2019 ; Vol. 31, No. 9. pp. 253-259.
@article{e02ed220eb394423a256e81768feb76e,
title = "Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention",
abstract = "BACKGROUND: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires administration of large contrast volume. The DyeVert system (Osprey Medical) is a disposable, Food and Drug Administration (FDA)-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in cardiac catheterization. METHODS: We compared the procedural outcomes of patients in whom the DyeVert system was used vs those in whom it was not used during CTO-PCI at a single center between 2017 and 2018. RESULTS: The DyeVert system was used in 39 of 134 CTO-PCIs performed in 130 patients (30{\%}). Most patients (79{\%}) were men and the mean age was 66.6 ± 10.9 years. The most common target vessel was the right coronary artery (54.5{\%}), followed by the left anterior descending artery (26.1{\%}), and circumflex artery (15.7{\%}). The median contrast volume used in DyeVert patients was significantly lower (200 mL [interquartile range, 153-256 mL] vs 250 mL [interquartile range, 170-303 mL]; P=.04). There were no in-hospital major complications with the DyeVert system, nor device-related procedural complications. One patient in the DyeVert group had contrast-induced nephropathy following CTO-PCI that did not require dialysis. CONCLUSION: Use of the DyeVert system is feasible during CTO-PCI and may reduce the contrast volume administered to the patient. Additional larger studies with a primary clinical endpoint are needed to confirm these findings.",
keywords = "acute outcomes, chronic total occlusion, contrast reduction, percutaneous coronary intervention",
author = "Peter Tajti and Iosif Xenogiannis and Allison Hall and Burke, {M. Nicholas} and Ivan Chavez and Santiago Garcia and Mario G{\"o}ssl and Michael Mooney and Anil Poulose and Paul Sorajja and Yale Wang and Evangelia Vemmou and Ilias Nikolakopoulos and Pamela Morley and Rangan, {Bavana Venkata} and Imre Ungi and Brilakis, {Emmanouil S}",
year = "2019",
month = "9",
day = "1",
language = "English (US)",
volume = "31",
pages = "253--259",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "9",

}

TY - JOUR

T1 - Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention

AU - Tajti, Peter

AU - Xenogiannis, Iosif

AU - Hall, Allison

AU - Burke, M. Nicholas

AU - Chavez, Ivan

AU - Garcia, Santiago

AU - Gössl, Mario

AU - Mooney, Michael

AU - Poulose, Anil

AU - Sorajja, Paul

AU - Wang, Yale

AU - Vemmou, Evangelia

AU - Nikolakopoulos, Ilias

AU - Morley, Pamela

AU - Rangan, Bavana Venkata

AU - Ungi, Imre

AU - Brilakis, Emmanouil S

PY - 2019/9/1

Y1 - 2019/9/1

N2 - BACKGROUND: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires administration of large contrast volume. The DyeVert system (Osprey Medical) is a disposable, Food and Drug Administration (FDA)-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in cardiac catheterization. METHODS: We compared the procedural outcomes of patients in whom the DyeVert system was used vs those in whom it was not used during CTO-PCI at a single center between 2017 and 2018. RESULTS: The DyeVert system was used in 39 of 134 CTO-PCIs performed in 130 patients (30%). Most patients (79%) were men and the mean age was 66.6 ± 10.9 years. The most common target vessel was the right coronary artery (54.5%), followed by the left anterior descending artery (26.1%), and circumflex artery (15.7%). The median contrast volume used in DyeVert patients was significantly lower (200 mL [interquartile range, 153-256 mL] vs 250 mL [interquartile range, 170-303 mL]; P=.04). There were no in-hospital major complications with the DyeVert system, nor device-related procedural complications. One patient in the DyeVert group had contrast-induced nephropathy following CTO-PCI that did not require dialysis. CONCLUSION: Use of the DyeVert system is feasible during CTO-PCI and may reduce the contrast volume administered to the patient. Additional larger studies with a primary clinical endpoint are needed to confirm these findings.

AB - BACKGROUND: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires administration of large contrast volume. The DyeVert system (Osprey Medical) is a disposable, Food and Drug Administration (FDA)-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in cardiac catheterization. METHODS: We compared the procedural outcomes of patients in whom the DyeVert system was used vs those in whom it was not used during CTO-PCI at a single center between 2017 and 2018. RESULTS: The DyeVert system was used in 39 of 134 CTO-PCIs performed in 130 patients (30%). Most patients (79%) were men and the mean age was 66.6 ± 10.9 years. The most common target vessel was the right coronary artery (54.5%), followed by the left anterior descending artery (26.1%), and circumflex artery (15.7%). The median contrast volume used in DyeVert patients was significantly lower (200 mL [interquartile range, 153-256 mL] vs 250 mL [interquartile range, 170-303 mL]; P=.04). There were no in-hospital major complications with the DyeVert system, nor device-related procedural complications. One patient in the DyeVert group had contrast-induced nephropathy following CTO-PCI that did not require dialysis. CONCLUSION: Use of the DyeVert system is feasible during CTO-PCI and may reduce the contrast volume administered to the patient. Additional larger studies with a primary clinical endpoint are needed to confirm these findings.

KW - acute outcomes

KW - chronic total occlusion

KW - contrast reduction

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85071740448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071740448&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 253

EP - 259

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 9

ER -